严重急性呼吸综合征冠状病毒2（SARS-CoV-2）疫苗的研发
Development of vaccines for SARS-CoV-2.
作者信息
Ng Wern Hann, Liu Xiang, Mahalingam Suresh
机构信息
Emerging Viruses, Inflammation and Therapeutics Group, Menzies Health Institute Queensland, Griffith University (Gold Coast Campus), Queensland, Australia.
出版信息
F1000Res. 2020 Aug 17;9. doi: 10.12688/f1000research.25998.1. eCollection 2020.
Abstract
COVID-19 emerged in late 2019 and has rapidly spread through many countries globally. The causative SARS-CoV-2 virus was not known until recently, and there is little or no natural immunity in human populations. There is an urgent need for vaccines and drugs to combat this new pandemic. In just a few months, huge efforts and resources by government, academia, and industry have been thrown into the race to develop a vaccine. This brief review summarizes and discusses the array of technologies being applied to vaccine development, highlighting the strengths and weaknesses of the various approaches.
摘要
2019年末出现了新型冠状病毒肺炎（COVID-19），并迅速在全球许多国家传播。直到最近才发现致病的严重急性呼吸综合征冠状病毒2（SARS-CoV-2），人群中几乎没有或完全没有天然免疫力。迫切需要疫苗和药物来对抗这一新的大流行病。在短短几个月内，政府、学术界和工业界投入了巨大努力和资源，竞相研发疫苗。本简要综述总结并讨论了应用于疫苗研发的一系列技术，突出了各种方法的优缺点。
相似文献
1
Development of vaccines for SARS-CoV-2.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）疫苗的研发
F1000Res. 2020 Aug 17;9. doi: 10.12688/f1000research.25998.1. eCollection 2020.
2
SARS-CoV-2 SPIKE PROTEIN: an optimal immunological target for vaccines.SARS-CoV-2 刺突蛋白：疫苗的最佳免疫靶标。
J Transl Med. 2020 Jun 3;18(1):222. doi: 10.1186/s12967-020-02392-y.
3
Status of COVID-19 vaccine development.2019冠状病毒病疫苗的研发状况。
Tidsskr Nor Laegeforen. 2020 Sep 9;140(13). doi: 10.4045/tidsskr.20.0676. Print 2020 Sep 29.
4
Vaccine designers take first shots at COVID-19.疫苗研发人员首次对新冠病毒展开攻关。
Science. 2020 Apr 3;368(6486):14-16. doi: 10.1126/science.368.6486.14.
5
Current development of COVID-19 diagnostics, vaccines and therapeutics.新型冠状病毒肺炎诊断、疫苗和治疗药物的最新进展。
Microbes Infect. 2020 Jul-Aug;22(6-7):231-235. doi: 10.1016/j.micinf.2020.05.001. Epub 2020 May 6.
6
A vaccine is not too far for COVID-19.针对新冠病毒的疫苗已为时不远。
J Infect Dev Ctries. 2020 May 31;14(5):450-453. doi: 10.3855/jidc.12744.
7
mRNA Vaccines: Possible Tools to Combat SARS-CoV-2.信使核糖核酸疫苗：对抗严重急性呼吸综合征冠状病毒2的潜在工具
Virol Sin. 2020 Jun;35(3):259-262. doi: 10.1007/s12250-020-00243-0. Epub 2020 Jun 10.
8
Melanie Saville: the end-to-end process needed for a SARS-CoV-2 vaccine.梅兰妮·萨维尔：SARS-CoV-2 疫苗所需的端到端流程。
Bull World Health Organ. 2020 Sep 1;98(9):588-589. doi: 10.2471/BLT.20.030920.
9
COVID-19 vaccine development pipeline gears up.新冠疫苗研发进程加速推进。
Lancet. 2020 Jun 6;395(10239):1751-1752. doi: 10.1016/S0140-6736(20)31252-6.
10
Intensifying vaccine production.加强疫苗生产。
Bull World Health Organ. 2020 May 1;98(5):302-303. doi: 10.2471/BLT.20.020520.
引用本文的文献
1
The Future of mRNA Vaccines: Potential Beyond COVID-19.信使核糖核酸疫苗的未来：超越新冠病毒的潜力
Cureus. 2025 May 21;17(5):e84529. doi: 10.7759/cureus.84529. eCollection 2025 May.
2
Safety and Immunogenicity of the Live Attenuated Vaccine QazCOVID-Live Against Coronavirus Infection COVID-19: Pre-Clinical Study Results.减毒活疫苗QazCOVID-Live预防冠状病毒感染COVID-19的安全性和免疫原性：临床前研究结果
Vaccines (Basel). 2024 Dec 12;12(12):1401. doi: 10.3390/vaccines12121401.
3
How a Novel Approach of Allergy Call Center Improved the Management of the Anti-COVID Vaccination Campaign in Piedmont: Italy.一种新型过敏呼叫中心方法如何改善意大利皮埃蒙特地区抗新冠疫苗接种运动的管理
J Epidemiol Glob Health. 2024 Dec;14(4):1764-1770. doi: 10.1007/s44197-024-00309-2. Epub 2024 Oct 14.
4
Exploring the Relation Between Health Literacy, Infodemic, and Acceptance of COVID-19 Vaccination in Iran: A Cross-Sectional Study.探究伊朗健康素养、信息疫情与新冠疫苗接种接受度之间的关系：一项横断面研究。
Health Lit Res Pract. 2024 Oct;8(4):e184-e193. doi: 10.3928/24748307-20240607-01. Epub 2024 Oct 8.
5
A single-dose intranasal live-attenuated codon deoptimized vaccine provides broad protection against SARS-CoV-2 and its variants.单剂鼻内接种减毒活疫苗可提供针对 SARS-CoV-2 及其变体的广泛保护。
Nat Commun. 2024 Aug 26;15(1):7225. doi: 10.1038/s41467-024-51535-y.
6
COVID-19: An Overview of SARS-CoV-2 Variants-The Current Vaccines and Drug Development.新型冠状病毒肺炎（COVID-19）：严重急性呼吸综合征冠状病毒 2 型（SARS-CoV-2）变异株概述——当前疫苗和药物研发进展。
Biomed Res Int. 2023 Aug 29;2023:1879554. doi: 10.1155/2023/1879554. eCollection 2023.
7
The Effect of COVID-19 Vaccine on Women's Reproductive Health: A Cross-Sectional Study.新冠疫苗对女性生殖健康的影响：一项横断面研究。
Cureus. 2023 Jun 7;15(6):e40076. doi: 10.7759/cureus.40076. eCollection 2023 Jun.
8
Structural and non-structural proteins in SARS-CoV-2: potential aspects to COVID-19 treatment or prevention of progression of related diseases.SARS-CoV-2 的结构蛋白和非结构蛋白：COVID-19 治疗或预防相关疾病进展的潜在方面。
Cell Commun Signal. 2023 May 15;21(1):110. doi: 10.1186/s12964-023-01104-5.
9
The Breadth of Bacteriophages Contributing to the Development of the Phage-Based Vaccines for COVID-19: An Ideal Platform to Design the Multiplex Vaccine.噬菌体在 COVID-19 噬菌体疫苗开发中的广泛应用：设计多价疫苗的理想平台。
Int J Mol Sci. 2023 Jan 12;24(2):1536. doi: 10.3390/ijms24021536.
10
Microfluidic Manufacture of Lipid-Based Nanomedicines.基于脂质的纳米药物的微流体制备
Pharmaceutics. 2022 Sep 14;14(9):1940. doi: 10.3390/pharmaceutics14091940.
本文引用的文献
1
ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques.ChAdOx1 nCoV-19 疫苗可预防恒河猴的 SARS-CoV-2 肺炎。
Nature. 2020 Oct;586(7830):578-582. doi: 10.1038/s41586-020-2608-y. Epub 2020 Jul 30.
2
An mRNA Vaccine against SARS-CoV-2 - Preliminary Report.mRNA 疫苗对 SARS-CoV-2 的作用-初步报告。
N Engl J Med. 2020 Nov 12;383(20):1920-1931. doi: 10.1056/NEJMoa2022483. Epub 2020 Jul 14.
3
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial.一种基于重组腺病毒 5 型的 COVID-19 疫苗的安全性、耐受性和免疫原性：一项剂量递增、开放标签、非随机、首次人体试验。
Lancet. 2020 Jun 13;395(10240):1845-1854. doi: 10.1016/S0140-6736(20)31208-3. Epub 2020 May 22.
4
The race for coronavirus vaccines: a graphical guide.新冠疫苗竞赛：图解指南
Nature. 2020 Apr;580(7805):576-577. doi: 10.1038/d41586-020-01221-y.
5
The potential danger of suboptimal antibody responses in COVID-19.新冠肺炎中抗体反应欠佳的潜在危险。
Nat Rev Immunol. 2020 Jun;20(6):339-341. doi: 10.1038/s41577-020-0321-6.
6
The COVID-19 vaccine development landscape.2019冠状病毒病疫苗的研发情况。
Nat Rev Drug Discov. 2020 May;19(5):305-306. doi: 10.1038/d41573-020-00073-5.
7
A codon-pair deoptimized live-attenuated vaccine against respiratory syncytial virus is immunogenic and efficacious in non-human primates.一种密码子对去优化的活减毒呼吸道合胞病毒疫苗在非人灵长类动物中具有免疫原性和有效性。
Vaccine. 2020 Mar 23;38(14):2943-2948. doi: 10.1016/j.vaccine.2020.02.056. Epub 2020 Feb 24.
8
The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health - The latest 2019 novel coronavirus outbreak in Wuhan, China.新型冠状病毒持续的2019 - nCoV疫情对全球健康构成威胁——中国武汉最新的2019新型冠状病毒爆发。
Int J Infect Dis. 2020 Feb;91:264-266. doi: 10.1016/j.ijid.2020.01.009. Epub 2020 Jan 14.
9
First Ebola vaccine approved.首款埃博拉疫苗获批。
Nat Biotechnol. 2020 Jan;38(1):6. doi: 10.1038/s41587-019-0385-7.
10
Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry.抗体依赖增强作用促进冠状病毒进入的分子机制。
J Virol. 2020 Feb 14;94(5). doi: 10.1128/JVI.02015-19.
Zotero 插件